Eco Animal Health AI Stock Analysis
Want to see GB:EAH full AI Analyst Report?
Eco Animal Health (EAH) AI Stock Analysis
Eco Animal Health
(LSE:EAH)
The score is driven mainly by improving fundamentals supported by a very strong, low-leverage balance sheet and positive recent cash flow, partially offset by a clearly bearish technical setup (price below all key moving averages with negative MACD) and a relatively high P/E without a provided dividend yield.
Eco Animal Health (EAH) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 55.05M
- Dividend Yield
- ―
- Average Volume (3M)
- 157.63K
- Price to Earnings (P/E)
- 25.5
- Beta (1Y)
- 0.66
- Revenue Growth
- 9.96%
- EPS Growth
- 29.72%
- Country
- UK
- Employees
- 213
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Eco Animal Health Business Overview & Revenue Model
Company Description
ECO Animal Health Group plc, established in 1972 and based in New Malden, United Kingdom, focuses on the worldwide research, regulatory approval, and distribution of veterinary pharmaceutical solutions. The company's offerings include Aivlosin, a mac...
Eco Animal Health Financial Statement Overview
Summary
Financials are improving but still rebuilding. Income statement momentum is positive (FY2026 revenue rebound and higher operating/net profit), the balance sheet is very strong with very low leverage, and cash flow is solidly positive in FY2026—though historical volatility in revenue/profit and uneven cash generation temper the score.
Income Statement
62PositiveBalance Sheet
86Very PositiveCash Flow
67Positive| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 87.53M | 87.53M | 79.60M | 89.42M | 85.31M | 82.19M |
| Gross Profit | 42.50M | 42.50M | 35.91M | 37.68M | 36.75M | 33.70M |
| EBITDA | 8.39M | 8.06M | 7.29M | 6.53M | 7.41M | 3.62M |
| Net Income | 2.19M | 2.19M | 1.69M | 1.05M | 1.01M | -686.00K |
Balance Sheet | ||||||
| Total Assets | 118.56M | 118.56M | 120.60M | 123.27M | 121.31M | 113.60M |
| Cash, Cash Equivalents and Short-Term Investments | 25.43M | 25.43M | 25.01M | 22.37M | 21.66M | 14.31M |
| Total Debt | 4.93M | 4.93M | 3.79M | 4.03M | 4.48M | 1.91M |
| Total Liabilities | 23.05M | 23.05M | 25.84M | 29.89M | 25.76M | 19.25M |
| Stockholders Equity | 87.09M | 87.09M | 85.50M | 83.69M | 83.27M | 82.06M |
Cash Flow | ||||||
| Free Cash Flow | 7.54M | 7.54M | 5.44M | 4.79M | 10.03M | -3.25M |
| Operating Cash Flow | 7.73M | 7.73M | 10.45M | 9.42M | 16.01M | -358.00K |
| Investing Cash Flow | -3.78M | -3.78M | -4.61M | -3.42M | -5.98M | -2.88M |
| Financing Cash Flow | -4.21M | -4.21M | -1.95M | -3.69M | -2.40M | -3.31M |
Eco Animal Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EAH, the sentiment is Negative. The current price of 82.50 is below the 20-day moving average (MA) of 92.35, below the 50-day MA of 95.24, and below the 200-day MA of 96.63, indicating a bearish trend. The MACD of -3.39 indicates Positive momentum. The RSI at 26.27 is Positive, neither overbought nor oversold. The STOCH value of 12.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:EAH.
Eco Animal Health Peers Comparison
Overall Rating
- GB:EAH61Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:EAH | 61Neutral | GBP 53.19M | 25.54 | 2.55% | ― | 9.96% | 29.72% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:EAH | Eco Animal Health | 82.50 | -6.00 | -6.78% |
Eco Animal Health Corporate Events
Eco Animal Health wins key USDA safety nod for new poultry vaccine
PositiveEco Animal Health has secured a key regulatory milestone for its new poultry vaccine in the US. The United States Department of Agriculture’s Center for Veterinary Biologics has confirmed that field safety trial data for ECOVAXXIN MS, a vaccine targe...
Eco Animal Health Grants New Equity Awards to Top Executives
PositiveEco Animal Health has granted nominal cost conditional share options over 404,526 ordinary shares, around 0.60% of its issued capital, to chief executive David Hallas and chief financial officer Chris Wilks under its Long Term Incentive Plan. These a...
Eco Animal Health Wins Full Shareholder Backing at AGM as Vaccine Strategy Advances
PositiveEco Animal Health Group plc, a UK‑based global veterinary pharmaceuticals specialist, develops branded treatments to boost livestock productivity and welfare, led by its Aivlosin antibiotic for pigs and poultry. The company is building a next‑generat...
Eco Animal Health bolsters board with industry veteran as vaccine-led growth accelerates
PositiveEco Animal Health Group, an AIM-quoted global veterinary pharmaceuticals business, specialises in branded treatments that improve livestock welfare and productivity, led by its flagship antibiotic Aivlosin for pigs and poultry. The UK-based company,...
Eco Animal Health details director option exercises and related party vaccine licence
PositiveEco Animal Health has disclosed that CEO David Hallas and CFO Christopher Wilks have exercised nominal cost share options granted under the company’s long-term incentive plan, with the resulting shares provided from the firm’s employee benefit trust...
Eco Animal Health Secures Exclusive Licence for Sheep Toxoplasmosis Vaccine
PositiveEco Animal Health has signed a perpetual exclusive global in‑licensing agreement with French biotech Vaxinano for a late‑stage sheep vaccine candidate against toxoplasmosis, covering all key sheep‑rearing markets. The technology is patent‑protected a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026